Medicare Enrolled
Dr. Oscar Signori, MD
Hematology & Oncology · Dearborn, MI
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Signori from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Signori?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Signori
Dr. Oscar Signori is a hematology & oncology specialist in Dearborn, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Signori performed 4,442 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Signori received a total of $3,565 from 47 pharmaceutical and/or device companies across 136 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Signori is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 23% volume in MI
$3,565 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗4,442
Medicare services
Top 23% in MI for hematology & oncology
Not available
Unique patients (not deduplicated)
$42
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 2,280 | $18 | $72 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
888 | $95 | $376 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
193 | $12 | $51 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
155 | $102 | $443 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
155 | $68 | $265 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
126 | $6 | $25 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
115 | $40 | $113 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
98 | $11 | $42 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
97 | $8 | $23 |
| New patient office visit, complex (60-74 min) | 62 | $176 | $648 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
57 | $1 | $5 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
41 | $49 | $221 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
31 | $62 | $206 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
28 | $8 | $10 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
25 | $61 | $267 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
24 | $92 | $294 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
23 | $100 | $392 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $138 | $535 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $42 | $166 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
11 | $41 | $166 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
4.4% high complexity
62.0% medium
33.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,565
Total received (2018-2024)
Avg $509/year across 7 years
Top 35% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
136
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,127
2023
$836
2022
$958
2021
$276
2020
$60
2019
$113
2018
$195
Payments by company (2024)
Astellas Pharma US Inc
$140
Novartis Pharmaceuticals Corporation
$131
Daiichi Sankyo Inc.
$128
Janssen Biotech, Inc.
$99
PFIZER INC.
$72
AstraZeneca Pharmaceuticals LP
$55
Gilead Sciences, Inc.
$55
Genentech USA, Inc.
$48
Karyopharm Therapeutics Inc.
$46
E.R. Squibb & Sons, L.L.C.
$46
RECORDATI_RARE_DISEASES_INC.
$45
Blueprint Medicines Corporation
$38
Incyte Corporation
$28
JAZZ PHARMACEUTICALS INC.
$27
Acrotech Biopharma Inc.
$25
Exelixis Inc.
$24
BeiGene USA, Inc.
$23
Celgene Corporation
$20
Eisai Inc.
$18
Deciphera Pharmaceuticals Inc.
$17
Stemline Therapeutics Inc.
$15
Boston Scientific Corporation
$15
EMD Serono, Inc.
$14
Top 3 companies account for 35.4% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$491
Novartis Pharmaceuticals Corporation
$315
Amgen Inc.
$309
SANOFI-AVENTIS U.S. LLC
$252
Seagen Inc.
$157
AVEO Pharmaceuticals, Inc.
$141
AstraZeneca Pharmaceuticals LP
$140
PFIZER INC.
$139
Daiichi Sankyo Inc.
$128
Janssen Biotech, Inc.
$99
GENZYME CORPORATION
$96
Takeda Pharmaceuticals U.S.A., Inc.
$90
Gilead Sciences, Inc.
$88
Genentech USA, Inc.
$83
Sirtex Medical Inc
$79
Karyopharm Therapeutics Inc.
$73
EISAI INC.
$64
E.R. Squibb & Sons, L.L.C.
$63
Celgene Corporation
$58
Eisai Inc.
$54
Acrotech Biopharma Inc.
$49
Incyte Corporation
$48
RECORDATI_RARE_DISEASES_INC.
$45
Stemline Therapeutics Inc.
$38
Blueprint Medicines Corporation
$38
BeiGene USA, Inc.
$36
SOBI, INC
$28
JAZZ PHARMACEUTICALS INC.
$27
Alnylam Pharmaceuticals Inc.
$26
Exelixis Inc.
$24
Alexion Pharmaceuticals, Inc.
$24
PharmaEssentia USA Corporation
$21
Servier Pharmaceuticals LLC
$20
SERVIER PHARMACEUTICALS LLC
$20
Bayer HealthCare Pharmaceuticals Inc.
$19
Merck Sharp & Dohme LLC
$19
Rigel Pharmaceuticals, Inc.
$18
MAYNE PHARMA INC.
$17
Deciphera Pharmaceuticals Inc.
$17
Aveo Pharmaceuticals, Inc.
$17
G1 Therapeutics, Inc.
$16
Janssen Pharmaceuticals, Inc
$16
Lilly USA, LLC
$15
Boston Scientific Corporation
$15
EMD Serono, Inc.
$14
Kite Pharma, Inc.
$13
MorphoSys, US Inc.
$12
Top 3 companies account for 31.3% of all-time payments
Associated products mentioned in payments ›
AYVAKIT · BELEODAQ · BESREMI · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · COSELA · DARZALEX · Doptelet · Enhertu · FEMARA · FOTIVDA · Fabhalta · IBRANCE · IMFINZI · Itovebi · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LUMAKRAS · Lenvima · MEKINIST · MONJUVI · Neulasta · Nplate · ONPATTRO · ONUREG · Orserdu · PADCEV · PLUVICTO · Padcev · Perjeta · QINLOCK · REBLOZYL · RETEVMO · Rezlidhia · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SYLVANT · Stivarga · TASIGNA · TECENTRIQ · TEVIMBRA · TIBSOVO · TUKYSA · Trodelvy · ULTOMIRIS · Venclexta · XARELTO · XPOVIO · Xtandi · ZEPZELCA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
125
County median income
$59,521
Nearest hospital to ZIP centroid (approximate)
BEAUMONT HOSPITAL - DEARBORN
3.8 mi
3.8 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Signori is a clinical cardiology specialist, with above-average Medicare volume (top 23% in MI), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Signori experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Signori performed 2,280 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Signori receive payments from pharmaceutical companies?
Yes. Dr. Signori received a total of $3,565 from 47 companies across 136 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Signori's costs compare to other hematology & oncology specialists in Dearborn?
Dr. Signori's average Medicare payment per service is $42. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Signori) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dearborn
Browse hematology & oncology specialists in Dearborn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology